Opinion: OA Advocates Slam Science Advances

Proponents of open-access publishing question the newly announced terms of publishing in the American Association for the Advancement of Science’s forthcoming journal.

Written byDalmeet Singh Chawla
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, DUNCAN HULLOpen access advocates, led by Imperial College London PhD student Jon Tennant, are drafting an open letter to the American Association for the Advancement of Science (AAAS), publisher of Science, outlining concerns over newly announced details for the organization’s forthcoming open-access journal Science Advances. Tennant and a bevvy of cosignatories argue that publishing in Science Advances places “unnecessary restrictions on reuse,” and that the journal does not meet the standards of the Budapest Open Access Initiative. (Full disclosure: I am a signatory on the draft open letter, and worked for the open-access publisher BioMed Central from 2012 to 2014.)

Like most open-access journals, Science Advances will be supported by article processing charges. But unlike other publications, the journal plans to charge an additional fee ($1,500) for processing articles longer than 10 pages. “In an online-only format, page length is an arbitrary unit that results from the article being read in PDF format,” Tennant et al. argued in their draft letter, which is being edited today on a collaborative Google Doc.

The authors also take issue with the new journal publishing papers, by default, under a Creative Commons Attribution-NonCommercial 2.0 Generic (CC-BY-NC) license, making researchers funded by organizations such as the Research Councils UK and the Wellcome Trust unable to submit their work. The open access advocates argue that non-commercial restrictions offer little benefit to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies